<DOC>
	<DOCNO>NCT01320332</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetics ( PK ) ass safety tolerability single dose ASP3291 subject ulcerative colitis .</brief_summary>
	<brief_title>A Study Single Dose ASP3291 Subjects With Ulcerative Colitis</brief_title>
	<detailed_description>After 11-day screening period , subject check clinic , dose Day 1 stay clinic 4 day monitor pharmacokinetic safety parameter .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Subject previously document diagnosis ulcerative colitis ( UC ) endoscopy histology consistent diagnosis If female , subject least 2 year postmenopausal surgically sterile per documentation provide third party medical professional subject agree use 2 highly effective method birth control study pregnant lactating Subject willing able comply study requirement Subject body mass index ( BMI ) &lt; 32 kg/m2 Subject ulcerative colitis require treatment 5aminosalicylic acid ( 5ASA ) Subject undergone previous resective colonic surgery Subject previously diagnose Crohn 's Disease base medical history Subject extension disease limit ulcerative proctitis Subject active peptic ulcer disease base medical history Subject currently treat prescription medication except follow : A stable dose 5aminosalicylic acid ( 5ASA ) least 2 week , oral contraceptive hormone replacement therapy ( HRT ) Subject history human immunodeficiency virus ( HIV ) Subject history severe allergic anaphylactic reaction Subject history drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Ulcerative colitis</keyword>
	<keyword>ASP3291</keyword>
</DOC>